TNF (tumor necrosis factor) is a pleiotropic cytokine involved in homeostasis and disease pathogenesis. Recent advances in TNF biology have led to new therapeutic strategies for TNF-mediated diseases. TNF signaling is mediated through two receptors, TNFR1 and TNFR2, which trigger distinct functional outcomes, such as inflammation, apoptosis, and necroptosis. The signaling pathways involve complex interactions, including linear ubiquitination and the formation of distinct signaling complexes. Understanding these pathways has enabled the development of therapies that selectively inhibit TNF's harmful effects while preserving its homeostatic functions. TNF is involved in both homeostatic and pathogenic processes. It is essential for immune defense, tissue repair, and maintaining organ function. However, excessive TNF activity contributes to inflammatory and autoimmune diseases. TNF has been targeted in various diseases, including rheumatoid arthritis, inflammatory bowel disease, psoriasis, and others. Recent studies have shown that TNF can also influence cancer, either by inducing carcinogenesis or promoting tumor progression. Additionally, TNF plays a role in cardiovascular disease, fibrosis, and Dupuytren's disease. Therapeutic strategies targeting TNF include global inhibition, which has shown success but is limited by adverse effects and the development of antibodies. Alternative approaches aim to selectively block pathogenic TNF activities while preserving homeostatic functions. These include targeting specific TNF receptors, such as TNFR1, or using biologic agents that selectively inhibit TNF signaling. Additionally, research into epigenetic regulators and chromatin modifications has provided new insights into TNF's role in disease and potential therapeutic targets. Despite progress, challenges remain in fully understanding TNF's biology and translating this knowledge into effective treatments. Future research should focus on elucidating the molecular mechanisms underlying TNF signaling, the role of epigenetic regulation, and the development of more targeted therapies. These advancements could lead to more effective and safer treatments for TNF-mediated diseases.TNF (tumor necrosis factor) is a pleiotropic cytokine involved in homeostasis and disease pathogenesis. Recent advances in TNF biology have led to new therapeutic strategies for TNF-mediated diseases. TNF signaling is mediated through two receptors, TNFR1 and TNFR2, which trigger distinct functional outcomes, such as inflammation, apoptosis, and necroptosis. The signaling pathways involve complex interactions, including linear ubiquitination and the formation of distinct signaling complexes. Understanding these pathways has enabled the development of therapies that selectively inhibit TNF's harmful effects while preserving its homeostatic functions. TNF is involved in both homeostatic and pathogenic processes. It is essential for immune defense, tissue repair, and maintaining organ function. However, excessive TNF activity contributes to inflammatory and autoimmune diseases. TNF has been targeted in various diseases, including rheumatoid arthritis, inflammatory bowel disease, psoriasis, and others. Recent studies have shown that TNF can also influence cancer, either by inducing carcinogenesis or promoting tumor progression. Additionally, TNF plays a role in cardiovascular disease, fibrosis, and Dupuytren's disease. Therapeutic strategies targeting TNF include global inhibition, which has shown success but is limited by adverse effects and the development of antibodies. Alternative approaches aim to selectively block pathogenic TNF activities while preserving homeostatic functions. These include targeting specific TNF receptors, such as TNFR1, or using biologic agents that selectively inhibit TNF signaling. Additionally, research into epigenetic regulators and chromatin modifications has provided new insights into TNF's role in disease and potential therapeutic targets. Despite progress, challenges remain in fully understanding TNF's biology and translating this knowledge into effective treatments. Future research should focus on elucidating the molecular mechanisms underlying TNF signaling, the role of epigenetic regulation, and the development of more targeted therapies. These advancements could lead to more effective and safer treatments for TNF-mediated diseases.